CD19xCD3 bispecific T-cell engager that redirects T cells to lyse CD19+ B-ALL blasts.
Bispecific T-cell engager that binds CD19 on B cells and CD3 on T cells, bringing them into proximity to activate T cells and induce perforin/granzyme-mediated lysis of CD19-positive B-ALL blasts.
YES
DIRECT
Blinatumomab bridges CD3+ T cells to CD19+ cells, activating T cells to release perforin and granzymes that lyse/apoptose CD19-expressing cells.
CD19xCD3 bispecific T-cell engager that redirects T cells to lyse CD19+ B-ALL blasts.
Bispecific T-cell engager that binds CD19 on B cells and CD3 on T cells, bringing them into proximity to activate T cells and induce perforin/granzyme-mediated lysis of CD19-positive B-ALL blasts.
NO
INDIRECT
Blinatumomab binds CD3 on T cells to activate and redirect them to lyse CD19+ cells via perforin/granzyme; CD3+ cells are not the killed targets.
Autologous T cells engineered with a CD19-specific chimeric antigen receptor to target and eliminate CD19+ B cells.
Autologous T cells are genetically modified to express a chimeric antigen receptor that binds CD19 on B cells. CAR engagement delivers CD3-zeta and costimulatory signals that activate the T cells to proliferate, release cytokines, and kill CD19-positive malignant B cells, resulting in targeted depletion of pathogenic B-cell populations.
YES
DIRECT
CD19-specific CAR T cells bind CD19 on target cells and, upon CAR activation, directly kill them via perforin/granzyme-mediated cytolysis and Fas–FasL apoptotic signaling.
CD19-directed chimeric antigen receptor T-cell therapy (engineered autologous T cells) administered intravenously in split doses; recognizes CD19 and, via CAR signaling, activates cytotoxicity to kill malignant B cells, resulting in B-cell depletion.
Autologous T cells genetically engineered to express a CD19-specific chimeric antigen receptor recognize CD19 on B-lineage malignant cells; CAR signaling activates T-cell cytotoxicity and cytokine release, leading to targeted lysis and depletion of CD19+ cells.
YES
DIRECT
CD19 CAR T cells bind CD19 on target cells and trigger T‑cell cytotoxicity, primarily via perforin/granzyme-mediated lysis and Fas–FasL apoptosis, leading to depletion of CD19+ cells.
Autologous CD4/CD8-enriched T cells engineered with a CD19-directed chimeric antigen receptor (CAR) that recognizes CD19 and eliminates CD19+ B-lineage cells, inducing B-cell aplasia and aiming to reset humoral autoimmunity in refractory SLE.
Autologous CD4+/CD8+ T cells engineered to express a CD19-directed chimeric antigen receptor that recognizes and eliminates CD19+ B-lineage cells, inducing B-cell aplasia, reducing autoantibody production, and aiming to reset humoral autoimmunity in refractory SLE.
YES
DIRECT
CAR-T cells recognizing CD19 bind CD19+ cells and kill them via T-cell cytotoxicity (perforin/granzyme release and Fas–FasL–mediated apoptosis).